According to our data, Blepharogel 1 and 2 are highly effective hygienic products for the treatment of chronic blepharitis of various etiologies. Daily use of Blepharogel for 1.5-2 months significantly improved the quality of life of the patients. Given its good tolerability, Blepharogel 1 and 2 can be recommended for wide use in the ophthalmologist practice for preventing and treating blepharitis and blepharoconjunctivitis of various etiologies, including demodectic, recurrent stye, as well as eye fatigue and dryness.
Combined therapy, which includes, in addition to anti-allergic treatment, the use of the Blepharogel 1, makes it possible to achieve a more pronounced and rapid reduction in the intensity of the subjective and objective symptoms of the summer-autumn pollinosic blepharoconjunctivitis than standard therapeutic treatment.
The use of Blepharogel 1 in a complex therapy of the summer-autumn pollinosic blepharoconjunctivitis allows for a greater increase in stability of the tear film than isolated anti-allergic treatment.
Including Blepharogel 1 in a complex treatment of the summer-autumn pollinosic blepharoconjunctivitis can reduce the intensity of the combined lipid- and mucinodeficit, as well as reduce the epitheliopathy phenomena of the eye surface tissues.
Use of Blepharogel 1 in a complex treatment of the summer-autumn pollinosic blepharoconjunctivitis improves the efficiency of the treatment.
Complex therapy consisting of anti-allergic treatment, tear replacement, and therapeutic eyelid hygiene (based on applying Blepharoshampoo, Blepharolotion or Blepharowipes, and Blepharogel 1) has a more powerful effect on reducing subjective symptoms and objective signs of chronic ABC (allergic blepharoconjunctivitis) than isolated anti-allergic and tear replacement therapy.